Trial
NCT02403323
Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Crohn Disease
Intervention
Etrolizumab
Why stopped
The study was terminated due to program discontinuation, based on mixed efficacy results in the parent studies. There were no safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-02